Overview

14-day Double Therapy Versus Bismuth Quadruple Therapy in First-line Treatment of Helicobacter Pylori Infection

Status:
Not yet recruiting

Trial end date:
2023-06-20

Target enrollment:

Participant gender:

Summary

The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomized to 14 days of dual therapy with Tegoprazan or 14 days of quadruple therapy with bismuth for eradication. At 6 weeks after treatment, subjects underwent another 13C-urea breath test. The eradication rate, adverse reaction rate and patient compliance were calculated.

Phase:

Phase 4

Details

Lead Sponsor:

Shandong University

Treatments:

Amoxicillin